China's IP protection found lacking in US trade report

The USTR’s 2017 report on China’s compliance with World Trade Organization rules has found certain deficiencies with regards to intellectual property protection in the area of pharmaceuticals.

The USTR, or Office of the United States Trade Representative, submits its annual report to the US Congress as part of its responsibility for developing and advising on the country’s trade policy.

The agency notes that, while China pledged to permit supplemental data supporting pharmaceutical patent applications in December 2013, the country has “not consistently implemented this commitment.”